GemPharmatech Co (SHSE:688046) ROIC %: 12.26% (As of Mar. 2026)


SHSE:688046 GemPharmatech Co Ltd SHSE:688046
95 GF Score
Price ¥23.04
GF Value ¥19.49
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is GemPharmatech Co ROIC %?

GemPharmatech Co SHSE:688046 -0.48% 95 ROIC % is 12.26% as of Mar. 2026. GuruFocus rates SHSE:688046 with a GF Score™ of 95/100 and a GF Value™ of ¥19.49 (Modestly Overvalued). The stock has 8 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. GemPharmatech Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 12.26%.

As of today (2026-07-07), GemPharmatech Co's WACC % is 18.38%. GemPharmatech Co's ROIC % is 11.33% (calculated using TTM income statement data). GemPharmatech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


GemPharmatech Co  (SHSE:688046) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, GemPharmatech Co's WACC % is 18.38%. GemPharmatech Co's ROIC % is 11.33% (calculated using TTM income statement data). GemPharmatech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


GemPharmatech Co ROIC % Related Terms


GemPharmatech Co ROIC % Historical Data

* Premium members only.

The historical data trend for GemPharmatech Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GemPharmatech Co ROIC % Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial 35.20 23.66 15.33 9.11 11.37

GemPharmatech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.46 12.92 11.60 8.93 12.26

SHSE:688046 vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, GemPharmatech Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GemPharmatech Co ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GemPharmatech Co's ROIC % distribution charts can be found below:

* The bar in red indicates where GemPharmatech Co's ROIC % falls into.


SHSE:688046
95GF Score
GemPharmatech Co Ltd SHSE:688046
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GemPharmatech Co ROIC % Calculation

GemPharmatech Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=181.987 * ( 1 - 13.51% )/( (1267.826 + 1501.069)/ 2 )
=157.4005563/1384.4475
=11.37 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2572.645 - 136.11 - ( 1168.709 - max(0, 371.196 - 1709.774+1168.709))
=1267.826

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2865.067 - 139.668 - ( 1244.314 - max(0, 527.144 - 1751.474+1244.314))
=1501.069

GemPharmatech Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=220.304 * ( 1 - 12.05% )/( (1501.069 + 1660.332)/ 2 )
=193.757368/1580.7005
=12.26 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2865.067 - 139.668 - ( 1244.314 - max(0, 527.144 - 1751.474+1244.314))
=1501.069

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2868.038 - 122.079 - ( 1085.627 - max(0, 477.623 - 1711.353+1085.627))
=1660.332

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 12.26% mean?
GemPharmatech Co (SHSE:688046) has a ROIC % of 12.26% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on GemPharmatech Co and its competitors.
Is GemPharmatech Co's ROIC % too high?
GemPharmatech Co's current ROIC % is 12.26%. Overall, GemPharmatech Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's ROIC % compare to VRTX and REGN?
GemPharmatech Co's ROIC % of 12.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current ROIC % is 12.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.49, compared to a current price of ¥23.04 — trading 18.2% above its estimated fair value. The current ROIC % is 12.26%. GemPharmatech Co's overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current ROIC % is 12.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?

Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued. The current stock price of ¥23.04 is trading 18.2% above its estimated GF Value™ of ¥19.49. GuruFocus considers GemPharmatech Co to be Modestly Overvalued.

Key valuation signals for SHSE:688046:

  • ROIC %: 12.26%
  • GF Value™: ¥19.49 vs. price of ¥23.04 (18.2% above fair value)
  • GF Score™: 95/100 with 8 warning signs

No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GemPharmatech Co Business Description

Address No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
95GF Score

Get the complete analysis for SHSE:688046

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.04
Price
¥19.49
GF Value